Issues with colorectal cancer and other solid cancers
Colorectal cancer stem cell issue is a peculiar case as until NOW no available medium for the in vitro growth. There are very few available drugs for colorectal cancer and they are not effective as problem is attributed to:
- The lack of the right medium (product) and technology for the study of colorectal cancer and other solid tumors have been a major concern hindering drug discovery and with the wrong starting material the end results are always not as expected or generally compromised.
- All clinical trial drugs are targeted towards cancer stem cells in the human body and having these cells in vitro is of great advantage to study the disease, identify the right molecules for drug discovery and screen the drugs for human use.
Huge problem and great challenge in the field.
Our innovative science and technology platforms, including our proprietary RhemaStem medium aims at addressing these issues by using a culture system that readily isolates and selects for bona fide stem cells in solid tumors allowing their perpetual propagation and establishment of stable cancer and normal stem cell lines.
RhemaStem has developed intellectual property skills and experience that allows for isolation and stable perpetuation of bona fide human colon cancer stem cells, circumventing the need for antigenic cell selection for the proliferation of tumour-initiating cells.
Stem cell culture protocol allows for establishment and significant expansion potential of colon cancer stem cells (CCSCs) from the human colorectal cancers
- Self-renewal capacity in vitro and in vivo.
- Culturing single stem cells from colon cancer stem cells validating the self-renewal capacity.
- Established stem cell lines injected orthotopically in the colon walls replicate the metastasis pattern in human.
- Established normal colon stem cells injected in the injured colon walls help repair and regenerate the affected sites by replacing lost or damaged cells, reducing inflammation.